Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 77

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 77
---
 |     | $                                | -1,163,216 |     | $                                                          |    414,344 |     | $                                                                                     |         — |     | $                                                                                 |  -322,827 |     | $                                                              |   -196,484 |     | $                                                            |   -229,900 |     | $                                                                                      |   164,883 |     |                            |           |

(3) Total Shareholder Return for each year reflects what the cumulative value of $100 would be if such amount were invested into our Company for that applicable year on December 31, 2021.

(4) Net (loss) or income as reported in our consolidated statements of operations and comprehensive (loss) income in our Annual Report on Form 10-K for the applicable year.

Analysis of the Information Presented in the Pay Versus Performance Table

The following chart sets forth the relationship between Compensation Actually Paid to Our PEO, the average of Compensation Actually Paid to Our Non-PEO NEOs and our total shareholder return over the period covering fiscal years 2022, 2023, and 2024. A large component of our executive compensation is equity-based to align compensation with performance, but also includes other appropriate incentives such as cash bonuses that are designed to incentivize our executives

<div align='center'>44</div>

to achieve annual corporate goals. We believe the equity-based compensation strongly aligns our PEO and Non-PEO NEOs’ interests with those of our shareholders to maximize long-term value and encourage long-term employment.

<div align='center'>45</div>

#### Director Compensation
We maintain a compensation program for our non-employee directors. Under our non-employee director compensation program as in effect during 2024, each non-employee director received the following amounts for their services on our Board:

Initial Equity Award . Upon a director’s initial election or appointment to our Board, the director received an option to purchase 7,600 shares (or, with respect to the Chairman of the Board, 8,266 shares) of our Common Stock, which award vests in substantially equal monthly installments over three years following the date of grant, subject to accelerated vesting upon a change in control and 5,933 RSUs to vest in three substantially equal annual installments, subject to accelerated vesting upon a change in control. Each non-employee director who was providing service on January 2, 2024 also received an initial equity award on such date.

Annual Equity Award . If